Sponsored by:

Business in the Burbs

Movers, shakers and newsmakers

Regeneron reaches royalty agreements for two medications


Regeneron Pharmaceuticals Inc., a biotech company based in Tarrytown, said it has entered into two royalty agreements with Novartis Pharma AG covering two medications that the companies have been developing.

Under the first royalty agreement, Regeneron said it is entitled to receive royalties on worldwide sales of Novartis’ canakinumab, a medication currently under regulatory review to treat inflammatory diseases. Under the second royalty agreement, Novartis is entitled to receive royalties on worldwide sales of a second-generation interleukin-1 Trap, another treatment for inflammatpry diseases, if development proceeds.

This entry was posted on Thursday, June 11th, 2009 at 1:04 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical



About this blog
Business in the Burbs is our online news blog about businesses based or operating in the Lower Hudson Valley. Visitors here will also find items of interest to consumers in the region. Most contributions are from business reporters and editors covering Westchester, Rockland and Putnam counties.


Get blog updates via email:

About the Authors


Other recent entries


Monthly Archives